KSR1 and hearing loss disorder: Previous studies indicate inhibition of the MAPK pathway by dabrafenib confers protection from cisplatin-induced hearing loss, and we sought to determine whether genetic KO of KSR1 and suppression of the pathway provides similar protection (Ingersoll et al., 2020, 2023).